Investor · 1 deal
Every published round Project X took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Synchron | Series C | 16 Dec 2022 | $110m | Participant | Startup Daily (7 Nov 2025), Techboard, SmartCompany (16 Dec 2022), Startup Daily (16 Dec 2022), SmartCompany (16 Dec 2022) |
Companies Project X has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Synchron | 16 Dec 2022, Series C | 1 | 0 |
Fund closes reported for Project X, as distinct from the investments it has made.
Companies Project X has backed that another company then bought. An exit for the holding, not a deal Project X did.
Stories naming Project X. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.